MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported second-quarter net income of $20.3 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Mountain View, California-based company said it had profit of 29 cents.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.

The biopharmaceutical company posted revenue of $49.4 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $8.3 million.

ChemoCentryx shares have increased 41% since the beginning of the year. In the final minutes of trading on Monday, shares hit $55.72, climbing sevenfold in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI

Automated Insights, source Associated Press News